Canaccord Genuity Group Issues Positive Forecast for AtriCure (NASDAQ:ATRC) Stock Price

AtriCure (NASDAQ:ATRC) had its price objective boosted by stock analysts at Canaccord Genuity Group from $55.00 to $67.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group‘s price target would suggest a potential upside of 2.24% from the company’s previous close.

A number of other analysts also recently issued reports on the company. Needham & Company LLC lifted their price target on AtriCure from $64.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler restated an “overweight” rating and set a $70.00 target price (up from $60.00) on shares of AtriCure in a research note on Wednesday. Weiss Ratings raised AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Stifel Nicolaus set a $65.00 price target on shares of AtriCure in a research note on Thursday, September 17th. Finally, Freedom Capital cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $61.80.

AtriCure Stock Up 8.5%

Shares of NASDAQ:ATRC traded up $5.12 during trading hours on Wednesday, reaching $65.53. The stock had a trading volume of 1,335,550 shares, compared to its average volume of 874,695. AtriCure has a 1 year low of $25.36 and a 1 year high of $66.02. The firm’s 50 day moving average is $56.03 and its 200-day moving average is $38.40. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of 312.06 and a beta of 1.23. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.23. The business had revenue of $154.45 million during the quarter, compared to analysts’ expectations of $151.05 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. Research analysts predict that AtriCure will post 0.29 earnings per share for the current fiscal year.

Insider Activity at AtriCure

In related news, Director Regina Groves sold 5,313 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $54.22, for a total transaction of $288,070.86. Following the transaction, the director owned 34,546 shares in the company, valued at $1,873,084.12. This trade represents a 13.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Salvatore Privitera sold 4,519 shares of AtriCure stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total value of $271,140.00. Following the transaction, the insider directly owned 142,745 shares in the company, valued at approximately $8,564,700. This trade represents a 3.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 30,622 shares of company stock valued at $1,626,003 in the last three months. 4.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of AtriCure in the second quarter valued at approximately $125,198,000. Bank of America Corp DE acquired a new stake in shares of AtriCure during the second quarter worth $24,465,000. Grandeur Peak Global Advisors LLC acquired a new stake in shares of AtriCure during the second quarter worth $16,435,000. Osterweis Capital Management Inc. purchased a new position in AtriCure in the 2nd quarter valued at $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in AtriCure in the 2nd quarter valued at $9,388,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

More AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported third-quarter earnings of $0.17 per share and revenue of $154.45 million, beating analyst estimates. The earnings result also improved from a loss per share in the year-ago quarter. AtriCure Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company expects 2026 revenue of $606 million to $610 million, roughly in line with consensus, and projects adjusted EBITDA of $91 million to $94 million. It also aims to complete BoxX-NoAF enrollment by year-end. AtriCure Projects 2026 EBITDA and Targets Enrollment Completion
• Positive Sentiment: Analyst revisions added support: Piper Sandler reaffirmed its overweight rating and raised its target to $70 from $60; Needham lifted its target to $70 from $64 and maintained a buy rating. BTIG also raised its target to $70. Analysts Boost Forecasts After Q3 Results
• Negative Sentiment: JPMorgan raised its price target substantially, from $36 to $62, but kept a neutral rating; the new target is below the current share price, signaling limited upside at that level. JPMorgan Analyst Recommendation

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.